论文部分内容阅读
目的评价安博维(厄贝沙坦)治疗原发性高血压1、2级患者的疗效及副作用。方法采用双盲随机对照方法,对106例高血压患者进行药物疗效观察,其中51例采用安博维治疗(治疗组),另55例采用苯磺酸氨氯地平(络活喜)治疗(对照组)。结果观察组的总有效率为96.1%,对照组的总有效率为80%,两组总有效率比较差异有统计学意义(P<0.05)。结论厄贝沙坦治疗1、2级高血压治疗效果显著,优于络活喜治疗,同时安博维使平均动脉压下降同时增加有效肾血液流量,对肾脏有明显的保护作用,值得临床借鉴。
Objective To evaluate the efficacy and side effects of Ambow (irbesartan) in the treatment of patients with grade 1 and 2 essential hypertension. Methods A double-blind randomized controlled trial was conducted in 106 hypertensive patients. Fifty-one patients were treated with ambroxetil (treatment group) and 55 were treated with amlodipine besylate (control group ). Results The total effective rate was 96.1% in the observation group and 80% in the control group. The total effective rate in the two groups was statistically significant (P <0.05). Conclusion Irbesartan treatment of grade 1 and 2 hypertension has a significant effect, which is better than that of loratotherapy. Meanwhile, AVB reduces mean arterial pressure and increases effective renal blood flow, which has a significant protective effect on the kidneys.